Greg Pyszczymuka Email

Chief Commercial Officer . Aytu BioScience

Current Roles

Employees:
137
Revenue:
$27.5M
About
Aytu BioScience, Inc. is a specialty healthcare company focused on developing treatments for urological and related conditions. The Company is currently completing Phase 3 clinical development for its lead therapeutic candidate Zertane™, an orally disintegrating tablet (ODT) formulated specifically for the on-demand treatment of premature ejaculation (PE). The Company's therapeutic pipeline is supported in part by its first-in-class RedoxSYS® System, which provides the only complete assessment of patients' redox status and enables identification of a broad variety of disorders where redox is implicated. Clinical studies are underway utilizing the RedoxSYS system in male fertility. The Company also recently acquired and is commercializing FDA-approved ProstaScint® (capromab pendetide), a radio-labeled monoclonal antibody, that targets Prostate Specific Membrane Antigen (PSMA), a protein uniquely expressed by prostate tissue. The Company's strategy is to develop its core therapeutic and diagnostic assets while building an innovative pipeline of established marketed products and late-stage development assets.
Aytu BioScience Address
373 Inverness Parkway
Centennial, CO
United States

Past Companies

Aytu BioPharmaChief Commercial Officer
Aytu BioPharmaExecutive Vice President, Commercial Operations
Neos Therapeutics, Inc.Vice President, Head of Commercial

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.